ArticleAllergy2019
The soluble isoform of human FcɛRI is an endogenous inhibitor of IgE-mediated mast cell responses.
Article in Allergy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Systemic Mastocytosis, KIT and the Effects of KIT Tyrosine Kinase Inhibitors on Mast Cell and Basophil Activation.Current allergy and asthma reports · 2026Review
- Rapid Change in FcεRI Occupancy on Basophils After Venom Immunotherapy Induction.International journal of molecular sciences · 2025Article
- Therapeutic Efficacy of YH35324 on FcεRIα-Mediated Mast Cell/Basophil Activation.Allergy, asthma & immunology research · 2025Article
- Comparative analyses of various IgE-mediated and non-IgE-mediated inducers of mast cell degranulation for in vitro study.Immunologic research · 2024Article
- In chronic spontaneous urticaria soluble FcεRI is elevated and linked to atopy and chronic inducible urticaria.Clinical and translational allergy · 2023Article
- Activation of Mast Cells by Neuropeptides: The Role of Pro-Inflammatory and Anti-Inflammatory Cytokines.International journal of molecular sciences · 2023Review
- Soluble IgE-binding factors in the serum of food-allergic patients: Possible pathophysiological role of soluble FcεRI as protective factor.Clinical and translational allergy · 2023Article
- New Mechanistic Advances in FcεRI-Mast Cell-Mediated Allergic Signaling.Clinical reviews in allergy & immunology · 2022Review
- M2 macrophage-related gene signature in chronic rhinosinusitis with nasal polyps.Frontiers in immunology · 2022Article
- Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management.Clinical reviews in allergy & immunology · 2021Review
- The relationship between released soluble FceRI-alpha and its cell surface density on human basophils.PloS one · 2021Article
- B cells and the microbiota: a missing connection in food allergy.Mucosal immunology · 2021Review
- Soluble FcεRI, IgE, and tryptase as potential biomarkers of rapid desensitizations for platin IgE sensitized cancer patients.The journal of allergy and clinical immunology. In practice · 2020Article
- Cell-bound IgE and plasma IgE as a combined clinical diagnostic indicator for allergic patients.Scientific reports · 2020Article
- AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer-a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI).Clinical and translational allergy · 2020Review
- Recent developments in understanding the mechanisms of food allergy.Current opinion in pediatrics · 2019Review
- Soluble FcɛRI: A biomarker for IgE-mediated diseases.Allergy · 2019Article
- CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen.The Journal of clinical investigation · 2019Article
- A new look at IgE beyond allergies.F1000Research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundThe soluble isoform of FcɛRI, the high-affinity IgE receptor (sFcεRI), is a protein of the IgE network with poorly defined functions.
objectiveTo define cellular sources and signals that result in the production of human sFcεRI and study its in vivo functions.
methodsFcεRI-transfected human cell lines (MelJuso), human monocyte-derived dendritic cells (moDCs), and murine bone marrow-derived mast cells (MC) were stimulated by FcεRI cross-linking and release of sFcεRI was analyzed (ELISA, Western Blot). Lysosomal-associated membrane protein 1 degranulation assays and human basophil activation tests (BATs) were used to study IgE-dependent activation. Recombinant sFcεRI (rsFcεRI) was used to assess its role in murine models of anaphylaxis with WT (wild-type) and IgE
resultsAntigen-specific cross-linking of IgE-loaded FcɛRI on MelJuso cells that express the trimeric or tetrameric receptor isoform induced the production of sFcεRI. Using MCs and moDCs, we confirmed that IgE/FcɛRI activation induces sFcɛRI release. We demonstrated that generation of sFcɛRI requires Src phosphorylation and endo/lysosomal acidification. In experimental mouse models, sFcɛRI diminishes the severity of IgE-mediated anaphylaxis. BATs confirmed that, comparable to the anti-IgE monoclonal antibody omalizumab, sFcɛRI is an inhibitor of the human innate IgE effector axis, implying that sFcɛRI and omalizumab potentially inhibit each other in vivo.
conclusionsFcɛRI is produced after antigen-specific IgE/FcɛRI-mediated activation signals and functions as an endogenous inhibitor of IgE loading to FcɛRI and IgE-mediated activation. Our results imply, therefore, that sFcɛRI contributes to a negative regulatory feedback loop that aims at preventing overshooting responses after IgE-mediated immune activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.